Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
August 19, 2022 01:00 ET
|
Cara Therapeutics, Inc.
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy...
Cara Therapeutics Reports Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET
|
Cara Therapeutics, Inc.
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia®...
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
August 01, 2022 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica
June 30, 2022 07:00 ET
|
Cara Therapeutics, Inc.
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical...
Cara Therapeutics to Present at Upcoming Investor Conferences
May 17, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 17, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET
|
Cara Therapeutics, Inc.
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia® (difelikefalin) approved by European Commission for the treatment of...
Cara Therapeutics to Present at May Investor Conferences
May 03, 2022 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
April 29, 2022 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives...
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
April 28, 2022 01:00 ET
|
Cara Therapeutics, Inc.
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland...